Harbor Capital Advisors Inc. Acquires 28,630 Shares of Avanos Medical, Inc. (NYSE:AVNS)

Harbor Capital Advisors Inc. lifted its position in shares of Avanos Medical, Inc. (NYSE:AVNS - Free Report) by 14,386.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 28,829 shares of the company's stock after purchasing an additional 28,630 shares during the quarter. Harbor Capital Advisors Inc. owned approximately 0.06% of Avanos Medical worth $413,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. boosted its stake in Avanos Medical by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 5,339,778 shares of the company's stock valued at $85,009,000 after buying an additional 19,476 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in shares of Avanos Medical by 27.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,011,312 shares of the company's stock valued at $47,941,000 after purchasing an additional 644,267 shares in the last quarter. Brown Advisory Inc. grew its holdings in shares of Avanos Medical by 12.0% in the 4th quarter. Brown Advisory Inc. now owns 1,905,094 shares of the company's stock worth $30,329,000 after purchasing an additional 204,218 shares during the last quarter. William Blair Investment Management LLC increased its position in shares of Avanos Medical by 2.1% during the 4th quarter. William Blair Investment Management LLC now owns 1,406,210 shares of the company's stock worth $22,387,000 after purchasing an additional 28,608 shares in the last quarter. Finally, Paradice Investment Management LLC lifted its holdings in Avanos Medical by 2.5% during the 4th quarter. Paradice Investment Management LLC now owns 1,293,198 shares of the company's stock valued at $20,588,000 after purchasing an additional 30,949 shares during the last quarter. 95.17% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of Avanos Medical from a "hold" rating to a "buy" rating in a report on Wednesday, March 19th.

Avanos Medical Price Performance

NYSE AVNS traded down $0.03 during midday trading on Wednesday, hitting $12.12. The company had a trading volume of 182,537 shares, compared to its average volume of 372,688. The firm has a 50-day moving average price of $12.50 and a 200-day moving average price of $14.69. The company has a market capitalization of $560.20 million, a PE ratio of -1.45 and a beta of 1.14. The company has a current ratio of 2.57, a quick ratio of 1.56 and a debt-to-equity ratio of 0.12. Avanos Medical, Inc. has a twelve month low of $11.84 and a twelve month high of $25.36.

Avanos Medical (NYSE:AVNS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.19 by $0.07. The business had revenue of $167.50 million during the quarter, compared to analyst estimates of $161.75 million. Avanos Medical had a negative net margin of 55.80% and a positive return on equity of 6.26%. The firm's quarterly revenue was up .8% on a year-over-year basis. During the same quarter last year, the business earned $0.22 EPS. As a group, analysts anticipate that Avanos Medical, Inc. will post 1.32 earnings per share for the current fiscal year.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.